NCT00127179已完成3 期
MK0906 Phase III Double-Blind Comparative Study - Benign Prostate Hyperplasia
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 600
- 主要终点
- Change from baseline in the International Prostate Symptom Score
研究概览
简要总结
The purpose of this trial is to determine the efficacy and safety of an investigational drug in patients with benign prostatic hyperplasia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 50 Years 至 79 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Patients with benign prostatic hyperplasia
排除标准
- •Patients who are suspected to be suffering from prostatic cancer
结局指标
主要结局
Change from baseline in the International Prostate Symptom Score
次要结局
- Change from baseline in maximum urinary flow rate, %
- Change from baseline in Prostate volume
- Change from baseline in QOL - index
研究者
相似试验
已完成
3 期
An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327)Rhinitis, Allergic, SeasonalNCT00127647Organon and Co1,375
已完成
3 期
Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)Major Depressive DisorderNCT00048594Merck Sharp & Dohme LLC800
已完成
3 期
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)Major Depressive DisorderNCT00035048Merck Sharp & Dohme LLC540
已完成
3 期
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)Major Depressive DisorderNCT00035282Merck Sharp & Dohme LLC450
已完成
3 期
Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)Prostate CancerNCT00060476Merck Sharp & Dohme LLC15,000